Status:
NOT_YET_RECRUITING
A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborating Sponsors:
Zhenjiang First People's Hospital
Changzhou First People's Hospital
Conditions:
Extranodal Natural Killer/T-cell Lymphoma
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study is a prospective, multicenter, open-label, single-arm clinical study. This study plans to enroll 72 newly diagnosed ENKTCL patients. The enrollment was completed in 2 years, and the follow-...
Eligibility Criteria
Inclusion
- newly diagnosed ENKTCL confirmed by pathological tissue, the diagnostic criteria refer to the 2016 WHO diagnostic criteria
- Sign written informed consent and be able to comply with the visits and related procedures specified in the protocol
Exclusion
- The investigator believes that the subjects may have other factors that may affect the efficacy or safety evaluation of this study
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT05343377
Start Date
June 1 2022
End Date
June 1 2028
Last Update
April 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China